For Health Innovators
You've built something that works. Now make it move.
C.H.I.E.F.S.™ gives you the commercialization read that funders, hospital systems, and strategic partners run internally — before they’ll sit across the table from you. Get it first. Fix what needs fixing. Walk in prepared.
"Most innovators don't fail because the science is weak. They fail because nobody told them what the buyer actually needs to see.
If you're advancing a health innovation, this is built for you.
C.H.I.E.F.S.™ works across every stage and category of health innovation — from pre-seed to pre-exit.
MedTech & Device Founders
You have cleared or are clearing regulatory hurdles. Now you need to show payers and procurement teams why this belongs in their system.
Digital Health & SaaS Builders
Your platform solves a real problem. C.H.I.E.F.S. helps you translate clinical utility into a procurement argument hospital administrators will act on.
Biotech & Therapeutics Teams
Pipeline progress is necessary but not sufficient. C.H.I.E.F.S. maps the commercial path alongside the clinical one — before your next raise.
Academic & IP Spinouts
Strong IP. Early traction. But the commercial path isn't clear yet. C.H.I.E.F.S. tells you exactly what's missing and what to build next.
Most health innovations that fail, fail for predictable reasons.
Ninety percent of health innovations that reach late-stage development still don't make it to meaningful scale. Not because the science failed. Because the commercial infrastructure wasn't built alongside it.
The gaps are consistent. The failure modes are well-documented. And nearly all of them are detectable — and fixable — before you've burned your next round.
The end user loves it. The person who signs the purchase order has never heard of it. Customer pillar failures account for the largest share of stalled deals.
Payers and procurement teams don't buy outcomes. They buy savings, displaced costs, and reduced risk. Health-Economics is where most pitches break down.
Freedom-to-operate problems, thin claims, and unprotected know-how — discovered by an acquirer's legal team, not yours.
The raise is sized for vision, not for milestones. The use of funds doesn't map to the commercialization path. Sophisticated investors notice.
Strategic acquirers and institutional investors need to see a plausible exit before they engage seriously. Most early-stage decks don't have one.
Not advice. A structured commercial read.
Five deliverables from a single C.H.I.E.F.S.™ evaluation.
An aggregate score out of 50
A single defensible number across all six pillars — the kind investors and acquirers run internally.
Factor-by-factor breakdown
Detailed scoring across all 10 factors and 50 criteria — so you know exactly where strength and weakness live.
Recommended actions by urgency
Not a list of things that would be nice to fix. A ranked set of actions ordered by what needs to happen first.
A live Q&A session with Dan
The evaluation runs live on Zoom. You present, we score, we talk. You leave the session already clearer before the written report arrives.
The written Findings Report
Delivered within 48 hours. Structured. Boardroom-ready. The document you can take to your investors, your team, and your next strategic conversation.
No NDA. No confidential materials.
We work entirely from public-domain inputs. You share nothing proprietary. The process protects you from day one.